Heparin plus aspirin as a 'single' therapy for recurrent spontaneous abortion associated with both allo- and autoimmunity

American Journal of Reproductive Immunology

Volumn 41, Issue 4, 1999, Pages 271-278

  Cadavid, Angela ^a   Peña, Beatriz ^a   García, Gloria ^a   Botero, Jorge ^a   Sánchez, Fabio ^a   Ossa, Jorge ^a   Beer, Alan ^b  

^a UNIVERSIDAD DE ANTIOQUIA   (Colombia)

^b ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

Author keywords

Alloimmunity; Aspirin; Autoimmunity; Heparin; Recurrent spontaneous abortion

Indexed keywords

ACETYLSALICYLIC ACID; ASPIRINETA; FEPA HEPARINA; HEPARIN; UNCLASSIFIED DRUG;

ADULT; ALLOIMMUNITY; ARTICLE; AUTOIMMUNITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; LYMPHOCYTE; MATERNAL CARE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SPONTANEOUS ABORTION;

EID: 0344435232     PISSN: 10467408     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0897.1999.tb00438.x     Document Type: Article

References (56)

1. Beer AE: Immunologic aspects of normal pregnancy and recurrent spontaneous abortion. Semin Reprod Endocrinol 1988; 6:163-178.
2. Gleicher N, El-Roeiy A, Confino E, Friberg J: Reproductive failure because of autoantibodies: Unexplained infertility and pregnancy wastage. Am J Obstet Gynecol 1989; 160:1367-1385.
3. Clark DA: Controversies in reproductive immunology. Crit Rev Immunol 1991; 11:215-247.
4. Rote NS: Antiphospholipid antibodies and recurrent pregnancy loss. Am J Reprod Immunol 1996; 35:394-401.
5. McIntyre JA, McConnachie PR, Taylor CG, Faulk WP: Clinical and genetic definitions of primary and secondary recurrent spontaneous abortion. Fertil Steril 1984; 42:849-855.
6. The Recurrent Miscarriage Immunotherapy Trialists Group: Worldwide collaborative observational study and meta-analysis on allogenic leukocyte immunotherapy for recurrent spontaneous abortion. Am J Reprod Immunol 1994;32:55-72.
7. Parazzini F, Acaia B, Faden D, Lovotti M, Marelli G, Cortelazzo S: Antiphospholipid antibodies and recurrent abortion. Obstet Gynecol 1991; 77:854-858.
8. Gatenby PA, Cameron K, Shearman RP: Pregnancy loss with phospholipid antibodies: Improved outcome with aspirin containing treatment. Aust NZ Obstet Gynaecol 1989; 29:294-298.
9. Cowchock FS, Reece EA, Balaban D, Branch DW, Plouffe L: Repeated fetal losses associated with antiphospholipid antibodies: A collaborative randomized trial comparing prednisone with low-dose heparin treatment. Am J Obstet Gynecol 1992; 155:1318-1323.
10. Silveira LH, Hubble CL, Jara LJ, Saway S, Martinez-Osuna P, Seleznick MJ, Angel J, O'Brien W, Espinoza LR: Prevention of anticardiolipin antibody-related pregnancy losses with prednisone and aspirin. Am J Med 1992; 93:403-411.
11. Balasch J, Carmona F, Löpez-Soto A, Font J, Creus M, Fábregues F, Ingelmo M, Vanrell JA: Low-dose aspirin for prevention of pregnancy losses in women with primary antiphospholipid syndrome. Hum Reprod 1993; 12:2234-2239.
12. Krause I, Blank M, Gilbrut B, Shoenfeld Y: The effect of aspirin on recurrent fetal loss in experimental antiphospholipid syndrome. Am J Reprod Immunol 1993; 29:155-161.
13. McIntyre JA, Taylor CG, Torry DS, Wagenknecht DR, Wilson J, Faulk WP: Heparin and pregnancy in women with a history of repeated miscarriages. Haemostasis 1993; 23:202-211.
14. Coulam CB: Alternative treatment to lymphocyte immunization for treatment of recurrent spontaneous abortion; Immunotherapy with intravenous immunoglobulin for treatment of recurrent pregnancy loss: American experience. Am J Reprod Immunol 1994; 32:286-289.
15. Rosove MH, Tabsh K, Wasserstrum N, Howard P, Hahn BH, Kalunian KC: Heparin therapy for pregnant women with lupus anticoagulant or anticardiolipin antibodies. Obstet Gynecol 1995; 75:630-634.
16. Kwak JYH, Gilman-Sachs A, Beaman KD, Beer AE: Reproductive outcome in women with recurrent spontaneous abortion of alloimmune and autoimmune causes: preconception versus postconception treatment. Am J Obstet Gynecol 1992; 166:1787-1798.
17. Kutteh WH: Antiphospholipid antibody-associated recurrent pregnancy loss: Treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. Am J Obstet Gynecol 1996; 174:1584-1589.
18. Rai R, Cohen H, Dave M, Regan L: Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). BMJ 1997; 314:253-257.
19. Gensini GF, Bonechi F, Gori AM, Fortini A, Paniccia R, Lamberti R, Attanasio M, Martini F, Frisco D, Neri Serneri GG: Low-dose heparin as an antithrombotic agent. Haemostasis 1990; 20:129-131.
20. Ermel LD, Marshburn PB, Kutteh WH: Interaction of heparin with antiphospholipid antibodies (APA) from the sera of women with recurrent pregnancy loss (RPL). Am J Reprod Immunol 1995; 33:14-20.
21. Patrono C: Aspirin as an antiplatelet drug. N Engl J Med 1994; 330:1287-1294.
22. Fishman P, Falach-Vaknin E, Sredni B, Meroni PL, Tincani A, Dicker D, Shoenfeld Y: Aspirin-Interleukin-3 interrelationships in patients with anti-phospholipid syndrome. Am J Reprod Immunol 1996; 35:80-84.
23. Athanassakis I, Bleackley C, Paetkau V, Guilbert L, Barr PJ, Wegmann TG: The immunostimulatory effect of T cells and T cell lymphokines on murine fetally derived placental cells. J Immunol 1987; 138:37-44.
24. Beer AE, Kwak JY: What is the evidence for immunologic pregnancy loss?: Lymphocyte immunization, the supportive view. In Cellular and Molecular Biology of Materno-Fetal Relationship, G Chaouat, J Mowbray (eds). Paris, INSERM, John Libbey Eurotext, 1991, pp. 285-292.
25. Peña RB, Cadavid AP, Botero JH, Garcia GP, Gallego MI, Ossa JE: The production of MLR blocking factors does not predict the outcome of pregnancy. Am J Reprod Immunol 1998; 39:120-124.
26. Kwak JYH, Gilman-Sachs A, Beaman KD, Beer AE: Autoantibodies in women with primary recurrent spontaneous abortion of unknown etiology. J Reprod Immunol 1992; 22:15-31.
27. Mowbray JF, Underwood JL: Effect of paternal lymphocyte immunisation on birth-weight and pregnancy outcome. In Cellular and Molecular Biology of the Materno-Fetal Relationship, G Chaouat, J Mowbray (eds). Paris, INSERM, John Libbey Eurotext, 1991, pp. 295-302.
28. McIntyre JA, Coulam CB, Faulk WP: Recurrent spontaneous abortion. Am J Reprod Immunol 1989; 21:100-104.
29. Sánchez-Guerrero J, Alarcón-Segovia Donato: Course of antiphospholipid antibodies in patients with primary antiphospholipid syndrome before, during and after pregnancy treated with low dose aspirin: Relationship of antibody levels to outcome in 7 patients. J Rheumatol 1992; 19:1083-1088.
30. Rote NS, Walter A, Lyden TW: Antiphospholipid antibodies: Lobsters or red herrings? Am J Reprod Immunol 1992; 28:31-37.
31. Adler RR, Ng A-K, Rote NS: Monoclonal antiphosphatidylserine antibody inhibits intercellular fusion of the choriocarcinoma line, JAR. Biol Reprod 1995; 53:905-910.
32. Sher G, Feinman M, Zouves C, Kuttner G, Maassarani G, Salem R, Matzner W, Ching W, Chong P: High fecundity rates following in-vitro fertilization and embryo transfer in antiphospholipid antibody seropositive women treated with heparin and aspirin. Human Reprod 1994; 9:2278-2283.
33. Kutteh WH, Yetman DL, Chantilis SJ, Crain J: Effect of antiphospholipid antibodies in women undergoing in-vitro fertilization: Role of heparin and aspirin. Hum Reprod 1997; 12:1171-1175.
34. Hatasaka HH, Branch DW, Kutteh WH, Scott JR: Autoantibody screening for infertility: Explaining the unexplained? J Reprod Immunol 1997; 34:137-153.
35. Beer AE, Kwak-Kim JYH: Assessment of antiphospholipid antibodies in IVF-relevance to incidence and success rates. Serono Symposium 1997.
36. Carson DD, Wilson OF, Dutt A: Glycoconjugate expression and interactions at the cell surface of mouse uterine epithelial cells and periimplantation-stage embryos. In Trophoblast Research, H-W Denker, JD Aplin (eds). NY and London, Plenum, 1990, pp. 211-41.
37. Farach MC, Tang JP, Decker GL, Carson DD: Heparin/heparan sulfate is involved in attachment and spreading of mouse embryos in vitro. Dev Biol 1987; 123:401-410.
38. Lindahl U, Lidholt K, Spillmann D, Kjellén L: More to "heparin" than anticoagulation. Thromb Res 1994; 75:1-32.
39. Tyrrell DJ, Kilfeather S, Page CP: Therapeutic uses of heparin beyond its traditional role as an anticoagulant. Trends Pharmacol Sci 1995; 16:198-204.
40. Lider O, Baharav E, Mekori YA, Miller T, Naparstek Y, Vlodavsky I, Cohen IR: Suppression of experimental autoimmune diseases and prolongation of allograft survival by treatment of animals with low doses of heparins. J Clin Invest 1989; 83:752-756.
41. Sy MS, Schneeberger E, McCluskey R, Greene MI, Rosenberg RD, Benacerraf B: Inhibition of delayed-type hypersensitivity by heparin depleted of anticoagulant activity. Cell Immunol 1983; 82:23-32.
42. Lider O, Mekori YA, Miller T, Bar-Tana R, Vlodavsky I, Baharav E, Cohen IR, Naparstek Y: Inhibition of T lymphocyte heparanase by heparin prevents T cell migration and T cell-mediated immunity. Eur J Immunol 1990; 20:493-499.
43. Lagodzinski Z, Görski A, Wasik M: Immunosuppressive action of low-dose heparin: Effect on skin allograft survival. Transplantation 1990; 50:714-715.
44. Akyührek LM, Funa K, Wanders A, Larsson E, Fellström BC: Inhibition of transplant arterioesclerosis in rat aortic grafts by low molecular weight heparin derivatives. Transplantation 1995; 59:1517-1524.
45. Naparstek E, Slavin S, Weiss L, Sidi H, Ghana M, Reich S, Vlodavsky I, Cohen IR, Naparstek Y: Low-dose heparin inhibits acute graft versus host disease in mice. Bone Marrow Transplant 1993; 2:185-189.
46. Herold BC, Gerber SI, Polonsk T, Belval BJ, Shaklee PN, Holme K: Identification of structural features of heparin required for inhibition of Herpes Simplex Virus Type 1 binding. Virology 1995; 206:1108-1116.
47. Pearce-Pratt R, Phillips DM: Sulfated polysaccharides inhibit lymphocyte-to-epithelial transmission of Human Immunodeficiency Virus-1. Biol Reprod 1996; 54:173-182.
48. Johann S, Zoller C, Haas S, Blümel G, Lipp M, Förster R: Sulfated polysaccharide anticoagulant suppress natural killer cell activity in vitro. Thromb Haemost 1995;74:998-1002.
49. Yamamoto H, Fuyama S, Arai S, Sendo F: Inhibition of mouse natural killer cytotoxicity by heparin. Cell Immunol 1985; 96:409-417.
50. de Fougerolles AR, Baines MG: Modulation of the natural killer cell activity in pregnant mice alters the spontaneous abortion rates. J Reprod Immunol 1987; 11:147-153.
51. Higuchi K, Aoki K, Kimbara T, Hosoi N, Yamamoto T, Okada H: Suppression on natural killer cell activity by monocytes following immunotherapy for recurrent spontaneous aborters. Am J Reprod Immunol 1995; 33:221-227.
52. Kwak JY, Kwak FM, Ainbinder SW, Ruiz AM, Beer AE: Elevated peripheral blood natural killer cells are effectively downregulated by immunoglobulin G infusion in women with recurrent spontaneous abortions. Am J Reprod Immunol 1996; 35:363-369.
53. Ruiz JE, Kwak YH, Baum L, Gilman-Sachs A, Beaman KD, Kim YB, Beer AE: Intravenous immunoglobulin inhibits natural killer cell activity in vivo in women with recurrent spontaneous abortion. Am J Reprod Immunol 1996; 35:370-375.
54. Faulk WP: Haemostasis and fibrinolysis in human normal placentae: Possible role in early pregnancy failure. In Early Pregnancy Loss, Mechanisms and Treatment, RW Beard (ed). Ashton-Under-Lyne, Peacock Press, 1988, pp. 193-198.
55. Esmon CT: The regulation of natural anticoagulant pathways. Science 1987; 235:1348-1352.
56. Oosting JD, Derksen RH, Bobbink IWG, Hackeng TM, Bouma BN, de Groot PG: Antiphospholipid antibodies direct against a combination of phospholipids with prothrombin, protein C, or protein S: An explanation for their pathogenic mechanism? Blood 1993; 10:2618-2625.